Mr. Arthur Shannon reports

BAUSCH HEALTH PROVIDES APRISO INTELLECTUAL PROPERTY LITIGATION UPDATE

Bausch Health Companies Inc., along with its wholly owned subsidiary, Salix Pharmaceuticals, have agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA Inc. regarding Apriso (mesalamine) extended-release capsules 0.375 gram.

Under the terms of the agreement, Salix will grant Teva a non-exclusive licence, effective Oct. 1, 2021, to the Salix intellectual property relating to Apriso in the United States. Bausch Health will not make any financial payments or other transfers of value as part of the agreement.

The parties have agreed to dismiss all litigation related to Apriso and intellectual property protecting Apriso will remain intact and enforceable. The company will continue to vigorously defend its intellectual property. The final patent expiry on Apriso is 2030.

Bausch Health has also amended its prior sublicence agreement with Lupin Pharmaceuticals Inc. Two other paragraph 4 filings remain.

About Bausch Health Companies Inc.

Bausch Health is a global company whose mission is to improve people's lives with its health care products. The company develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.

We seek Safe Harbor.